Clinical trials / NCT07365332
NCT07365332Phase 3Recruiting

An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

Study sponsor: Inhibikase Therapeutics

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov recordCSV export · Pro
Primary completion2029-06Estimated
Enrollment · participants486Estimated
Source updated2026-09-02Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 1 field changed

Recruitment status changed

− Before

Not yet recruiting

+ After

Recruiting

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: [Part A] To evaluate the effect on PVR in participants with WHO Group 1 PAH treated with IKT-001 compared to placebo Measure: [Part B] To characterize the effects of IKT-001 on symptoms and characteristics of Pulmonary Arterial Hypertension compared to placebo

+ After

Measure: [Part A] To evaluate the effect on Pulmonary Vascular Resistance (PVR) in participants with WHO Group 1 PAH treated with IKT-001 compared to placebo Measure: [Part B] To characterize the effects of IKT-001 on symptoms and characteristics of Pulmonary Arterial Hypertension compared to placebo

Check registry source